ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2499

Tocilizumab Achieves Rapid Reduction of Disease Activity and Has Beneficial Effects on Bone Mineral Density in Patients with Rheumatoid Arthritis

Maria Hoehle, Rheumatology, Hamburg, Germany

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Disease Activity, osteo-anabolics, outcomes, rheumatoid arthritis (RA) and tocilizumab

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, November 15, 2016

Session Title: Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Tocilizumab achieves rapid reduction of disease activity and has beneficial effects on bone mineral density in patients with rheumatoid arthritis

Maria Höhle, MD1

1Orthopedic, Medical, Rheumatologic Center, Hamburg, Germany

Background/Purpose: Tocilizumab (TCZ) leads to a rapid improvement of the clinical course in patients with highly active rheumatoid arthritis (RA). However, a residual rheumatic activity can still be detected.1 RA is a known risk factor for osteoporosis related bone fractures.2 It is well established that TCZ has beneficial effects on bone remodeling.3

The aim of this analysis was to investigate the effects of TCZ on bone mineral density in a real world patient population.

 

Methods: 50 rheumatoid factor positive patients with RA (17 male, age 20-72 years) who received TCZ as monotherapy since 2008 were prospectively investigated. At baseline and the following 4-6 clinical visits, DAS28 was determined and ultrasound performed. At baseline and every 6 months thereafter, biochemical parameters for bone metabolism and protein diagnostics were recorded. Once a year, the subjects underwent MRI, CT and DXA scan.

 

Results: In all 50 patients the DAS28 normalized at the latest by the 3rd infusion cycle of TCZ. The initial RAMRIS score of >5 was reduced to <2 after 6-18 months. Ultrasound revealed a decline of synovialitis and tenodynovialitis after 8 weeks and 12 months, respectively. At baseline in 22 women with early RA, axial QCT/DXA values and lateral DXA values were within reference. 3 patients with early RA had osteopenia, 2 had osteoporosis. Patients with manifest RA had a BMD in the reference range, 3 had osteopenia and 2 were diagnosed with osteoporosis. In 6 male patients, BMD values were within the reference range. 2 men with early RA had osteopenia and 2 had manifest osteoporosis. In 1 male patient with manifest RA, normal BMD values were documented. 2 men with manifest RA hat osteopenia and 4 had osteoporosis. 10 patients had vitamin D3 deficiency and were treated with vitamin D3. 2 patients with osteoporosis were treated with antiresorptive medication. In all patients, BMD values were within the reference range after 1 year of treatment with TCZ, despite 18% of patients presenting with a DAS score > 2.7. 2 patients presented with pustular dermatosis in the palms. No allergic reactions were observed.

 

Conclusion: Treatment with TCZ leads to a rapid decline of inflammatory activity of the affected joints in patients with RA and minimizes cartilage destruction. TCZ showed a positive effect on bone remodeling and therefore BMD. Thus, the risk for the development of osteoporosis and its related fractures can be minimized by TCZ treatment. Furthermore, TCZ has a positive effect on BMD in manifest RA thus preventing sarcopenia. Temporary elevations of DAS28 during TCZ therapy do not negatively affect BMD.

   


Disclosure: M. Hoehle, None;

To cite this abstract in AMA style:

Hoehle M. Tocilizumab Achieves Rapid Reduction of Disease Activity and Has Beneficial Effects on Bone Mineral Density in Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/tocilizumab-achieves-rapid-reduction-of-disease-activity-and-has-beneficial-effects-on-bone-mineral-density-in-patients-with-rheumatoid-arthritis/. Accessed January 15, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/tocilizumab-achieves-rapid-reduction-of-disease-activity-and-has-beneficial-effects-on-bone-mineral-density-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.